A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating an investigational drug, an oncolytic virus called
rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of
an investigational drug and also tries to define the appropriate dose of the investigational
drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Candel Therapeutics, Inc. National Institutes of Health (NIH)